by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
21/7/2022
June 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
US stocks slumped after Federal Reserve acknowledged the risk of recession
US stocks slumped after Federal Reserve reiterated its commitment to curb inflation and acknowledged the risk of recession. Central bank is expected to closely monitor the impact of its rate hikes on the economy. IPO market is still frozen, no oncology IPO was completed in last four months.
Antibody-Drug Conjugates
Enhertu recommended for approved in EU for HER2+ metastatic breast cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended by CHMP for approval in EU as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
Interleukin-15 and Interleukin-2
ImmunityBio and Alkermes presented positive data of their compounds at ASCO
ImmunityBio announced new positive data from the company’s pivotal Phase 2/3 trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (QUILT 3032) and Phase 2 trial in advanced pancreatic cancer (QUILT 88).
Cell Therapies
FDA approved Breyanzi as second line therapy of B cell lymphoma
FDA approved Breyanzi (liso-cel), a CD19-directed CAR T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Other Innovative Treatment Areas
China’s NMPA approves Tyvyt in esophageal cancer
NMPA approved an sNDA from Innovent Biologics for Tyvyt sintilimab to treat esophageal squamous cell in the first-line setting, in combination with chemotherapy.
Oncology Transactions
Regeneron will secure global rights to Libtayo from Sanofi for $900 million upfront
A Sino Biopharm subsidiary’s acquisition of F-star represents will add a pipeline of tetravalent bispecifics and a STING program.
DISCLAIMER / SOTIO
Legal Notice
The material contained in this document was prepared based on information from public and private sources that SOTIO believes to be reliable. It is protected by copyright law and cannot be further disseminated or used for any commercial purposes without SOTIO´s prior written consent.
Sdílet na sociálních sítích